MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

Rhea-AI Summary

MIMEDX (NASDAQ: MDXG) has published significant health economics data in the Journal of Drugs in Dermatology regarding their EPIFIX® placental allograft product for wound reconstruction after Mohs surgery. The study of 429 Mohs patients demonstrated superior outcomes compared to traditional methods. Key findings include: - 97.2% of EPIFIX patients experienced no complications vs 78.7% with traditional methods - Average length of care reduced to 33.3 days vs 48.3 days for autologous tissue repairs - Substantial cost savings achieved through fewer complications and reduced additional procedures The data is particularly significant as Mohs surgery is performed over 850,000 times annually in the U.S. for treating common skin cancers. This research supports EPIFIX as an effective alternative to traditional surgical methods, particularly beneficial for high-risk surgeries and hospital systems focused on health economics.

Positive

• 97.2% of patients using EPIFIX experienced no complications vs 78.7% with traditional methods
• Reduced average length of care by 15 days (33.3 vs 48.3 days)
• Cost savings achieved through fewer postoperative complications
• Large market opportunity with over 850,000 annual Mohs procedures in the U.S.

Negative

• None.

News Market Reaction – MDXG

+4.75%

1 alert

+4.75% News Effect

On the day this news was published, MDXG gained 4.75%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company’s EPIFIX® Placental Allograft Product

MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX^® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology: “Placental allograft reconstruction of cutaneous wounds following Mohs surgery: a propensity score-matched comparative cost-effectiveness analysis.”

Mohs surgery is widely accepted as the gold standard for treating many types of skin cancer, including basal and squamous cell carcinomas, which are the most common cancers in the United States. MMS is performed over 850,000 times per year in the U.S., primarily by specially trained dermatologists operating in an outpatient setting. The procedure, which involves the removal of layers of cancerous skin tissue, typically ends with an autologous tissue-based closure over the treatment area. However, over the last several years, practitioners have increasingly started to evaluate the utility of placental allografts, such as EPIFIX, to aid in the closure of the impacted surface.

“We are thrilled to continue expanding the number of specialties and treatment applications that see real-world results with our products, both in terms of clinical success and cost-effectiveness,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “This retrospective study of 429 Mohs patients demonstrates the unique ability of our placental allografts to provide an alternative for those who are not suitable candidates for traditional surgical methods. We expect the data collected to inform clinicians and health policy makers of the benefits of innovative approaches in high-risk surgeries, particularly as hospital systems focus on health economics as a driving factor in decision-making.”

In the study, DHACM significantly reduced adverse post-repair sequelae, with 97.2% of patients experiencing no complications compared to 78.7% with traditional methods such as autologous tissue-based flaps and grafts. Placental allografts lead to substantial savings in these procedures by minimizing postoperative complications and reducing the need for additional procedures. Patients treated with placental tissue also reached closure faster, with an average length of care of 33.3 days compared to 48.3 days for those with autologous tissue repairs.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What are the key benefits of MIMEDX EPIFIX for Mohs surgery patients?

EPIFIX demonstrated 97.2% complication-free outcomes (vs 78.7% traditional), reduced care time to 33.3 days (vs 48.3 days), and achieved cost savings through fewer complications and procedures.

How many Mohs surgeries are performed annually in the United States?

Over 850,000 Mohs surgeries are performed annually in the U.S., primarily by specially trained dermatologists in outpatient settings.

What is the success rate of MDXG's EPIFIX in Mohs surgery?

According to the study, 97.2% of patients treated with EPIFIX experienced no complications, compared to 78.7% with traditional methods like autologous tissue-based flaps and grafts.

How does EPIFIX reduce healthcare costs in Mohs surgery?

EPIFIX reduces costs by minimizing postoperative complications, reducing the need for additional procedures, and shortening the length of care by approximately 15 days compared to traditional methods.